• 1. A novel electrochemical sensor for non-ergoline dopamine agonist pramipexole based on electrochemically reduced graphene oxide nanoribbons
  Prashanth S. Narayana,Nagappa L. Teradal,J. Seetharamappa,Ashis K. Satpati Anal. Methods 2015 7 3912
• 2. Recent advancement of biomass-derived porous carbon based materials for energy and environmental remediation applications
  Rishika Chakraborty,Vilya K,Mukul Pradhan,Arpan Kumar Nayak J. Mater. Chem. A 2022 10 6965

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines
• Catalysts and Inorganic Chemicals Inorganic Compounds Salt

Pramipexole dihydrochloride hydrate (CAS No. 191217-81-9): A Comprehensive Overview in Modern Pharmaceutical Research

Pramipexole dihydrochloride hydrate, identified by the Chemical Abstracts Service Number (CAS No.) 191217-81-9, is a well-documented pharmaceutical compound that has garnered significant attention in the field of medicinal chemistry and neuropharmacology. This compound is the dihydrochloride hydrate form of pramipexole, a well-known non-ergoline dopamine agonist primarily utilized in the treatment of motor symptoms associated with Parkinson's disease. Its molecular structure and pharmacological properties have been extensively studied, leading to a deeper understanding of its mechanisms of action and therapeutic applications.

The chemical structure of Pramipexole dihydrochloride hydrate features a complex arrangement of aromatic rings and functional groups, which contribute to its selective binding affinity for dopamine D2 and D3 receptors in the brain. This selectivity is crucial for its efficacy in managing Parkinsonian symptoms while minimizing side effects associated with broader dopaminergic stimulation. The dihydrochloride hydrate form enhances the stability and solubility of the compound, making it suitable for various pharmaceutical formulations.

Recent advancements in neuropharmacological research have highlighted the potential of Pramipexole dihydrochloride hydrate beyond its traditional applications. Studies have demonstrated its efficacy in addressing not only motor symptoms but also non-motor symptoms such as depression and anxiety, which are commonly observed in patients with Parkinson's disease. The compound's ability to modulate dopamine levels in specific brain regions has opened new avenues for treating neuropsychiatric disorders.

One of the most compelling aspects of Pramipexole dihydrochloride hydrate is its role in clinical trials investigating its potential benefits in conditions beyond Parkinson's disease. For instance, ongoing research explores its use in managing symptoms of Restless Legs Syndrome (RLS), a neurological disorder characterized by an irresistible urge to move the legs. The compound's ability to target dopamine receptors has shown promise in alleviating the debilitating symptoms associated with RLS, improving the quality of life for affected individuals.

The pharmacokinetic profile of Pramipexole dihydrochloride hydrate has been thoroughly examined to optimize therapeutic dosing and minimize adverse effects. The compound exhibits moderate oral bioavailability and a relatively long half-life, allowing for once-daily dosing regimens. This feature enhances patient compliance and convenience, making it a preferred choice for long-term management of Parkinson's disease and related disorders. Additionally, studies have indicated that the hydrate form contributes to improved drug release profiles, ensuring sustained therapeutic levels in the bloodstream.

In terms of safety and tolerability, Pramipexole dihydrochloride hydrate has been widely recognized for its favorable adverse effect profile compared to other dopaminergic medications. Common side effects include nausea, dizziness, and sleep disturbances, which are generally mild and manageable. However, researchers continue to investigate strategies to mitigate these effects, particularly in vulnerable populations such as the elderly. Clinical trials have shown that dose titration and combination therapies can significantly reduce the incidence and severity of adverse reactions.

The synthesis and purification of Pramipexole dihydrochloride hydrate adhere to stringent pharmaceutical standards to ensure high purity and consistency. Advanced synthetic methodologies have been developed to optimize yield and minimize impurities, enhancing the overall quality of the final product. These advancements are critical for maintaining the efficacy and safety of the drug across different batches and formulations.

The role of computational chemistry and molecular modeling in understanding the interactions between Pramipexole dihydrochloride hydrate and biological targets has been increasingly emphasized in recent years. These computational approaches have facilitated rapid screening of potential drug candidates and provided insights into structural modifications that could enhance pharmacological properties. Such innovations are driving the development of next-generation dopamine agonists with improved therapeutic profiles.

Ethical considerations in clinical research involving Pramipexole dihydrochloride hydrate are paramount, ensuring that patient safety is prioritized throughout trials. Regulatory agencies have implemented rigorous guidelines to oversee these studies, ensuring that they are conducted ethically and scientifically soundly. The inclusion of diverse patient populations in clinical trials has further strengthened the evidence base supporting its use across different demographics.

The future prospects for Pramipexole dihydrochloride hydrate extend beyond its current applications, with ongoing research exploring novel therapeutic uses. Investigations into its potential role in neuroprotection against neurodegenerative diseases have generated considerable interest. Additionally, studies are examining its interactions with other neurotransmitter systems, which could lead to innovative combination therapies targeting multiple neurological disorders simultaneously.

In conclusion, Pramipexole dihydrochloride hydrate (CAS No. 191217-81-9) represents a significant advancement in neuropharmacological therapy for conditions such as Parkinson's disease and Restless Legs Syndrome. Its unique pharmacological properties, combined with a favorable safety profile, make it a cornerstone medication in modern treatment strategies. As research continues to uncover new applications and refine existing formulations, this compound is poised to remain at the forefront of neurological medicine.

• 1217601-58-5((S)-Pramipexole-(N-Propyl-2,2,3,3,3-d5) Dihydrochloride)
• 1254579-15-1((6S)-6-N-Ethyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine)
• 191712-81-9((S)-N6-Propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine dihydrochloride hydrate)
• 104632-27-1(Dexpramipexole dihydrochloride)
• 104617-51-8(6-Acetamido-2-amino-4,5,6,7-tetrahydrobenzothiazole)
• 908244-04-2(R-Pramipexole 2HCl Monohydrate)
• 104617-31-4(2-Benzothiazolamine, 4,5,6,7-tetrahydro-6-(1-piperidinyl)-,dihydrochloride)
• 104632-25-9((S)-Pramipexole Dihydrochloride)
• 104632-26-0((S)-Pramipexole)
• 104632-28-2((R)-Pramipexole 2HCl)